Impact of Humoral and Cellular Immunity on Ovarian Cancer Outcomes
Abstract
Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. Currently, surgery plus platinum-based chemotherapy is the standard treatment. However, individual response to therapy is highly variable and unpredictable: some women experience progression-free survival (PFS) of years while others progress during treatment or shortly thereafter. Eventually, most women develop and succumb to platinum-resistant disease. While there have been attempts to improve outcomes using immunotherapies, their success to date has been limited. Current trials now focus on chemo-immunotherapy combinations, acknowledging that platinum-based therapies remain an important part of treatment. However, no methods exist to identify who will respond to or fail treatments. Moreover, there are no clinically-validated interventions to improve treatment response or outcomes. This project aims to determine whether circulating anti-tumor antibodies (AAbs) may serve as these biomarkers. We propose the first-ever population-based study of the association between antibody-mediated, humoral immune responses to tumor antigens, the tumor microenvironment immune phenotype, and EOC outcome. Using banked biospecimens and data on women newly diagnosed with EOC, we will assess the relationship between anti-tumor antibodies and both therapy response and survival (Aim 1) and the antibodies' relationship to the immune response in tumors (Aim 2). We will then use this information to build statistical models to predict which women will and will not respond well to therapy (Aim 3).
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2022
- Accession Number
- AD1195989
Entities
People
- Esther Elishaev
- Francesmary Modugno
Organizations
- University of Pittsburgh